No description available.

Abdominal aortic aneurysm (AAA) is a disease of the aorta characterized by pathological remodeling and progressive weakening of the vessel resulting in the increased risk of rupture and sudden death. In a mouse model of the disease induced by chronic Angiotensin II (AngII) infusion, progression of AAAs is associated with reduced differentiation of smooth muscle cells (SMCs) at the site of lesion development. In the mouse model, the effectiveness of cyclooxygenase-2 (COX-2) inhibition for attenuating AAA progression is associated with maintenance of a differentiated SMC phenotype. However, the safety of COX-2 inhibitors is currently in question due to the increased risk of adverse cardiovascular events. Thus, it is crucial to identify mediators downstream of COX-2 that may provide new targets for treatment of this disease. Recent studies in humans and mouse models have suggested that the microsomal prostaglandin E synthase (mPGES-1) enzyme, which acts downstream of COX-2, may also be involved in the pathogenesis of the disease. We hypothesized that increased prostaglandin E2 (PGE2) synthesis resulting from the induction of both COX-2 and mPGES-1 may result in reduced differentiation of SMCs, and that disruption of this pathway would preserve the differentiated phenotype. To test this hypothesis, human aortic smooth muscle cells (hASMCs) were utilized to examine the effects of a variety of agents involved in AAA development and the COX-2 pathway. My findings suggest that one of the effects of exposing hASMCs to AngII involves a specific induction of mPGES-1 expression. Furthermore, although different COX-2-derived products may have opposing effects, mPGES-1-derived PGE2 may be the primary prostanoid synthesized by SMCs which functions to attenuate differentiation. Therefore, mPGES-1 inhibition may provide inhibition of PGE2 that is more specific than COX-2 inhibitor treatment and may serve as a therapeutic target for attenuating AAA progression by maintaining a differentiated SMC phenotype.

Vermeersiekte or ‘vomiting disease’ is an economically important disease of ruminants following ingestion of Geigeria species in South Africa. Sheep are more susceptible and poisoning is characterised by stiffness, regurgitation, bloat, paresis and paralysis. Geigeria aspera was collected in the Vrede district (27° 25′ 48″ S; 29° 9′ 36″ E), Free State Province. The plant material was dried, milled and the toxic principles, known as sesquiterpene lactones, were extracted and isolated following chromatographic procedures. Even though geigerin and ivalin were previously isolated, an unknown sesquiterpene lactone, isogeigerin acetate, was also purified. Mouse myoblast (C2C12) and rat embryonic cardiac myocyte (H9c2) cell lines were exposed to different concentrations of geigerin, ivalin, isogeigerin acetate and a commercially available sesquiterpene lactone, parthenolide. An in vitro colorimetric assay 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was used to assess cytotoxicity. The median effective concentrations (EC50) indicated that ivalin and parthenolide were significantly (p<0.05) more toxic than geigerin and isogeigerin acetate. A concentration-dependent cytotoxic response was observed in both cell lines, however, C2C12 cells were more sensitive. A high performance liquid chromatography (HPLC) analysis was used to evaluate the in vitro metabolism of parthenolide, following the addition of a mouse liver microsomal fraction. Results revealed that parthenolide, incubated with the microsomal fraction, undergoes enzymatic transformation to form a metabolite. / Dissertation (MSc (Veterinary Sciences))--University of Pretoria, 2020. / pt2021 / Paraclinical Sciences / MSc (Veterinary Sciences) / Unrestricted

Introdução: A infecção crônica pelo vírus da hepatite C (VHC) está associada à presença da resistência insulínica e da esteatose hepática, independentemente dos fatores metabólicos do hospedeiro. A alteração na enzima MTHFR resulta em hiperhomocisteinemia, que altera o metabolismo intracelular dos lipídios e pode estar relacionada à esteatose hepática e à fibrose, em portadores do VHC. A redução da atividade hepática da MTP resulta em acúmulo de gordura nos hepatócitos, contribuindo para a severidade da esteatose hepática e da fibrose em portadores do VHC. Como objetivos foram estudados os polimorfismos 677 C/T do gene da MTHFR e -493 G/T do gene da MTP e sua relação com as variáveis clínicas, bioquímicas e histológicas em pacientes com infecção crônica pelo VHC. Métodos: 174 pacientes sem tratamento prévio com RNA do VHC positivo e com biópsia hepática foram genotipados para o polimorfismo 677C/T da MTHFR por Restriction Fragment Length Polymorfism-Polimerase Chain (PCRRFLP) e para -493G/T da MTP, por sequenciamento. Todos os pacientes tinham marcadores negativos para doença de Wilson, hemocromatose e doença autoimune, e também tinham baixa ingesta alcoólica, com menos de 100g/semana. Variáveis bioquímicas foram analisadas no momento da realização da biópsia hepática. Resultados: A frequência do genótipo TT do gene MTHFR foi de 9,8% nos pacientes com genótipo não 1 do VHC. No entanto, foi encontrada associação entre o genótipo TT x CT /CC do polimorfismo do gene MTHFR, com o grau de esteatose e fibrose em ambos os genótipos da hepatite C (p < 0,05). Uma diferença significativa foi encontrada em níveis plasmáticos de homocisteína em pacientes com esteatose (p = 0,03). A frequência do genótipo GG+GT do gene MTP foi de 56,8% nos pacientes com genótipo 1 do VHC com fibrose hepática grau 3+4 (OR 1,8, IC 95% 1,3-2,3). Foi observada uma associação direta entre a presença da esteatose hepática nos pacientes com VHC com o genótipo GG+GT do polimorfismo -493G/T do gene da MTP independentemente do genótipo do VHC (OR = 0,4, IC 95% 0,2-0,8, p = 0,01). Conclusões: o genótipo TT do polimorfismo C677T do gene da MTHFR foi mais frequente no genótipo não 1 do VHC, independentemente da classificação histopatológica, assim como a frequência do genótipo CT + TT na presença de fibrose grau 1+ 2 e da esteatose hepática. A hiperhomocisteinemia foi altamente prevalente em indivíduos com esteatose. Por outro lado, a presença do alelo G do do polimorfismo -493G/T do gene da MTP está associada a uma menor expressão da MTP hepática, protegendo contra a esteatose em pacientes com VHC do Nordeste do Brasil. Estudos adicionais em outras populações são necessários para avaliar melhor o papel desses polimorfismos em indivíduos infectados pelo VHC / Background: Chronic hepatitis C (CHC) infection has been shown to promote insulin resistance and hepatic steatosis independent of host metabolic factors. A lower MTHFR activity is associated to hiperhomocysteinemia and also may be related to steatosis and fibrosis in CHC. Futhermore a reduction on hepatic MTP activity resulting in fatty liver and could contribute to the severity of hepatic steatosis and fibrosis in CHC. The aim was to investigate this this polymorphism in the 677 C/T MTHFR and -493G/T MTP genes and there relation with metabolic and histological variables in patients with CHC. Methods: One hundred seven-four untreated patients with viral RNA and liver biopsy were genotyped for the 677C/T MTHFR and 493G/T MTP polymorphisms. The 677C/T polymorphism of the MTHFR gene was identified by Restriction Fragment Length Polymorfism- Polimerase Chain (PCRRFLP) and the 493 G/T polymorphism of the MTP gene was determined by direct sequencing of the polymerase chain reaction products. All patients were negative for markers of Wilsons disease, hemochromatosis and autoimmune diseases and had current and past daily alcohol intake less than 100g/week. A set of metabolic markers were also measured at the time of liver biopsies. Results: Among subjects infected with CHC genotype non-1 the frequency of MTHFR genotypes TT was 9.8%. Nevertheless, association was found between the MTHFR genotype TT x CT/CC polymorphism and the degree of steatosis and fibrosis in both hepatitis C genotype (p < 0.05). A significant difference was found on plasma homocysteine levels in patients with steatosis (p=0.03). Among subjects infected with CHC genotype 1 with fibrosis grade 3+4 the frequency of MTP genotypes GG+GT was 56.8% (OR 1.8; CI 95% 1.3-2.3). Observed an association with steatosis as dependent variable identified in genotypes GG+GT as independent protective factors against steatosis (OR=0.4, CI 95% 0.2-0.8, p = 0.01). Conclusion: The presence of genotype TT of MTHFR C677T polymorphism was more common in CHC genotype non-1 infected patient regardless of histopathological classification and genotype CT+TT frequencies were significant in the presence of fibrosis grade 1+2 and of steatosis. On the other hand the presence of the G allele of MTP 493G/T, which is possibly associated with a lower MTP hepatic expression, protects against steatosis in CHC patients from northeast of Brazil. Additional studies in other populations are needed to further assess the role of this polimorphysm in CHC

<p>BACKGROUND: Abetalipoproteinemia (ABL) is a rare autosomal recessive disorder caused by mutations in the gene coding for microsomal triglyceride transfer protein (MTTP).</p><p>AIM: To characterize the genetic basis of ABL in two unrelated patients.</p><p>RESULTS: In the first patient, the substitution c.1911C>T in exon 12 of the <em>MTTP</em> gene, resulting in the protein substitution p.P552L, was discovered using mutation screening. The parents are heterozygous and the proband is a homozygous carrier of this substitution. Using restriction fragment length polymorphism (RFLP), 100 control subjects were analyzed and none carried the substitution indicating that it is a novel <em>MTTP </em>mutation. Sequencing of the other ABL patient showed that the proband carried a homozygous single base insertion, at position  c.2342IVS16+2-3insT, located at the donor splice-site of intron 16 resulting in skipping of exon 16 and truncation of the protein. The proband's mother is heterozygous for the insertion while the father does not carry the insertion. Multiplex ligation-dependent probe amplification (MLPA) did not identify any deletion encompassing exon 16 in the proband, father or mother. Nonpaternity was excluded using polymorphic markers from several chromosomes. Haplotype analysis using markers spanning chromosome 4 revealed  heterodisomy (two homologous chromosomes) of 4p and the distal part of 4q, and isodisomy (duplication of one chromosome) of 4q12-4q26.</p><p>CONCLUSION: These data show that the cause of ABL in one of the patients is a missense mutation, p.P552L, while the cause of ABL in the other patient is due to uniparental disomy, probably resulting from non-disjunstion in meiosis I.</p>

BACKGROUND: Abetalipoproteinemia (ABL) is a rare autosomal recessive disorder caused by mutations in the gene coding for microsomal triglyceride transfer protein (MTTP). AIM: To characterize the genetic basis of ABL in two unrelated patients. RESULTS: In the first patient, the substitution c.1911C&gt;T in exon 12 of the MTTP gene, resulting in the protein substitution p.P552L, was discovered using mutation screening. The parents are heterozygous and the proband is a homozygous carrier of this substitution. Using restriction fragment length polymorphism (RFLP), 100 control subjects were analyzed and none carried the substitution indicating that it is a novel MTTP mutation. Sequencing of the other ABL patient showed that the proband carried a homozygous single base insertion, at position  c.2342IVS16+2-3insT, located at the donor splice-site of intron 16 resulting in skipping of exon 16 and truncation of the protein. The proband's mother is heterozygous for the insertion while the father does not carry the insertion. Multiplex ligation-dependent probe amplification (MLPA) did not identify any deletion encompassing exon 16 in the proband, father or mother. Nonpaternity was excluded using polymorphic markers from several chromosomes. Haplotype analysis using markers spanning chromosome 4 revealed  heterodisomy (two homologous chromosomes) of 4p and the distal part of 4q, and isodisomy (duplication of one chromosome) of 4q12-4q26. CONCLUSION: These data show that the cause of ABL in one of the patients is a missense mutation, p.P552L, while the cause of ABL in the other patient is due to uniparental disomy, probably resulting from non-disjunstion in meiosis I.

Introdução: A infecção crônica pelo vírus da hepatite C (VHC) está associada à presença da resistência insulínica e da esteatose hepática, independentemente dos fatores metabólicos do hospedeiro. A alteração na enzima MTHFR resulta em hiperhomocisteinemia, que altera o metabolismo intracelular dos lipídios e pode estar relacionada à esteatose hepática e à fibrose, em portadores do VHC. A redução da atividade hepática da MTP resulta em acúmulo de gordura nos hepatócitos, contribuindo para a severidade da esteatose hepática e da fibrose em portadores do VHC. Como objetivos foram estudados os polimorfismos 677 C/T do gene da MTHFR e -493 G/T do gene da MTP e sua relação com as variáveis clínicas, bioquímicas e histológicas em pacientes com infecção crônica pelo VHC. Métodos: 174 pacientes sem tratamento prévio com RNA do VHC positivo e com biópsia hepática foram genotipados para o polimorfismo 677C/T da MTHFR por Restriction Fragment Length Polymorfism-Polimerase Chain (PCRRFLP) e para -493G/T da MTP, por sequenciamento. Todos os pacientes tinham marcadores negativos para doença de Wilson, hemocromatose e doença autoimune, e também tinham baixa ingesta alcoólica, com menos de 100g/semana. Variáveis bioquímicas foram analisadas no momento da realização da biópsia hepática. Resultados: A frequência do genótipo TT do gene MTHFR foi de 9,8% nos pacientes com genótipo não 1 do VHC. No entanto, foi encontrada associação entre o genótipo TT x CT /CC do polimorfismo do gene MTHFR, com o grau de esteatose e fibrose em ambos os genótipos da hepatite C (p < 0,05). Uma diferença significativa foi encontrada em níveis plasmáticos de homocisteína em pacientes com esteatose (p = 0,03). A frequência do genótipo GG+GT do gene MTP foi de 56,8% nos pacientes com genótipo 1 do VHC com fibrose hepática grau 3+4 (OR 1,8, IC 95% 1,3-2,3). Foi observada uma associação direta entre a presença da esteatose hepática nos pacientes com VHC com o genótipo GG+GT do polimorfismo -493G/T do gene da MTP independentemente do genótipo do VHC (OR = 0,4, IC 95% 0,2-0,8, p = 0,01). Conclusões: o genótipo TT do polimorfismo C677T do gene da MTHFR foi mais frequente no genótipo não 1 do VHC, independentemente da classificação histopatológica, assim como a frequência do genótipo CT + TT na presença de fibrose grau 1+ 2 e da esteatose hepática. A hiperhomocisteinemia foi altamente prevalente em indivíduos com esteatose. Por outro lado, a presença do alelo G do do polimorfismo -493G/T do gene da MTP está associada a uma menor expressão da MTP hepática, protegendo contra a esteatose em pacientes com VHC do Nordeste do Brasil. Estudos adicionais em outras populações são necessários para avaliar melhor o papel desses polimorfismos em indivíduos infectados pelo VHC / Background: Chronic hepatitis C (CHC) infection has been shown to promote insulin resistance and hepatic steatosis independent of host metabolic factors. A lower MTHFR activity is associated to hiperhomocysteinemia and also may be related to steatosis and fibrosis in CHC. Futhermore a reduction on hepatic MTP activity resulting in fatty liver and could contribute to the severity of hepatic steatosis and fibrosis in CHC. The aim was to investigate this this polymorphism in the 677 C/T MTHFR and -493G/T MTP genes and there relation with metabolic and histological variables in patients with CHC. Methods: One hundred seven-four untreated patients with viral RNA and liver biopsy were genotyped for the 677C/T MTHFR and 493G/T MTP polymorphisms. The 677C/T polymorphism of the MTHFR gene was identified by Restriction Fragment Length Polymorfism- Polimerase Chain (PCRRFLP) and the 493 G/T polymorphism of the MTP gene was determined by direct sequencing of the polymerase chain reaction products. All patients were negative for markers of Wilsons disease, hemochromatosis and autoimmune diseases and had current and past daily alcohol intake less than 100g/week. A set of metabolic markers were also measured at the time of liver biopsies. Results: Among subjects infected with CHC genotype non-1 the frequency of MTHFR genotypes TT was 9.8%. Nevertheless, association was found between the MTHFR genotype TT x CT/CC polymorphism and the degree of steatosis and fibrosis in both hepatitis C genotype (p < 0.05). A significant difference was found on plasma homocysteine levels in patients with steatosis (p=0.03). Among subjects infected with CHC genotype 1 with fibrosis grade 3+4 the frequency of MTP genotypes GG+GT was 56.8% (OR 1.8; CI 95% 1.3-2.3). Observed an association with steatosis as dependent variable identified in genotypes GG+GT as independent protective factors against steatosis (OR=0.4, CI 95% 0.2-0.8, p = 0.01). Conclusion: The presence of genotype TT of MTHFR C677T polymorphism was more common in CHC genotype non-1 infected patient regardless of histopathological classification and genotype CT+TT frequencies were significant in the presence of fibrosis grade 1+2 and of steatosis. On the other hand the presence of the G allele of MTP 493G/T, which is possibly associated with a lower MTP hepatic expression, protects against steatosis in CHC patients from northeast of Brazil. Additional studies in other populations are needed to further assess the role of this polimorphysm in CHC

Polychlorinated biphenyls (PCB) represent relevant persistent organopollutants of the environment and the estimated amount of PCB released into the environment is 750000 metric tons. White-rot fungi have been studied for long time due to their degradative potential toward various aromatic pollutants and it is known that these fungi are able to decompose PCB in vivo. Biodegradation of PCB by the fungus Pleurotus ostreatus was studied in the frame of this work. A high degradative efficiency of P. ostreatus was observed in the first set of experiments, even in the presence of relative high amount of added PCB. Fungus was able to transform 780±50 µg out of the intial amount 1000 µg in 20 ml of a cultivation media within 42 days. A decrease in toxicity was recorded during the degradation that suggests the suitability of this organism for a practical use in decontamination. In vitro experiments with purified laccase induced with Cu2+ from this fungus did not prove any participation of the enzyme in the first step of PCB transformation. The enzyme did not show an ability to degrade PCB even after purification from cultivation media containing PCB. It was found that the first step of PCB transformation can be performed by an intracellular process with microsomal fraction. A degradation of 44-67% was observed for...

A synthetic estrogen 17α-ethinylestradiol (EE2) is the main active component of the hormonal contraceptive pills. The rise of consumption of hormonal contraceptives has increased the risk of the back negative effects of EE2 to aquatic organisms. EE2 belongs to the endocrine disruptive compounds known for mimicking natural hormones. A more detailed examination of the transformation of this compound in vivo and in vitro can contribute to a better understanding of its negative effects. This master thesis is therefore devoted to the study of the metabolism of EE2 in two selected model organisms. The ligninolytic fungus Pleurotus ostreatus is the type of fungi with promising biodegradation ability to a lot of pollutants. These properties have led to numerous studies of the degradation potential of P. ostreatus towards EE2, with the possibility of removing this compound from the environment. EE2 has been degraded by the fungus P. ostreatus in vivo resulting in one hydroxylated metabolite, which estrogenic activity is in need for further study. In vitro studies were carried out with a microsomal fraction isolated from the mycelium of this fungus. The conversion of EE2 in vitro via CYPs dependent on NADPH has not been demonstrated, however using KHP as a cofactor, there was one metabolite of EE2 found,...

Thèse numérisée par la Division de la gestion de documents et des archives de l'Université de Montréal.